{
    "2018-06-05": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Health Care Select Sector SPDR Fund Experiences Big Inflow",
                "features": {
                    "keywords": [
                        "Health Care Select Sector",
                        "SPDR Fund",
                        "Big Inflow"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "AbbVie's rheumatoid arthritis drug succeeds in late-stage study",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "rheumatoid arthritis",
                        "drug",
                        "late-stage study",
                        "succeeds"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis",
                "features": {
                    "keywords": [
                        "Upadacitinib",
                        "Monotherapy",
                        "Phase 3 Study",
                        "Rheumatoid Arthritis",
                        "Endpoints"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}